Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy

Journal of Dermatology

Volumn 32, Issue 3, 2005, Pages 204-209

  Nomura, Eriko ^a   Isoda, Ken Ichi ^a   Yamanaka, Keiichi ^a   Yamaguchi, Motoko ^a   Hakamada, Arata ^a   Mizutani, Hitoshi ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Angiocentric; CD56; Multi drug resistance; NK cell

Indexed keywords

CARBOPLATIN; CD19 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; T CELL INTRACELLULAR ANTIGEN 1; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOLOGY; LYMPHADENOPATHY; NATURAL KILLER CELL LYMPHOMA; SKIN DEFECT; STOMACH TUMOR; T CELL LYMPHOMA;

EID: 17044378649     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2005.tb00746.x     Document Type: Article

References (22)

1. The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists, Pathol Int, 50: 696-702, 2000.
2. Chan JKC, Jaffe ES, Ralfkiaer E, et al: Extranodal NK/T-cell lymphoma, nasal type, in: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC press, Lyon, France, 2001, P 204.
3. Jaffe ES, Chan JK, Su IJ, et al: Report of the workshop on nasal and related extra nodal angiocentric T/Natural Killer Cell lymphomas. Definitions, differential diagnosis, and epidemiology, Am J Surg Pathol, 20: 103-111, 1996.
4. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group, Blood, 84: 1361-1392, 1994.
5. Kanavaros P, Lescs MC, Briere J, et al: Nasal T-cell lymphoma: A clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus, Blood, 81: 2688-2695, 1993.
6. Siu LL, Chan JK, Kwong YL, Kwong YL: Natural killer cell malignancies: Clinicopathologic and molecular features, Histol Histopathol, 17: 539-554, 2002.
7. Yamaguchi M, Kita K, Miwa H, et al: Frequent Expression of P-Glycoprotein/MDR1 by Nasal T-Cell Lymphoma Cell, Cancer, 76: 2351-2356, 1995.
8. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K: P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporine A and its analogue, PSC 833, Blood, 93: 599-606, 1999.
9. Drenou B, Lamy T, Amiot L, et al: CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance, Blood, 89: 2966-2974, 1997.
10. Okamoto M, Maruyama F, Tsuzuki M, et al: Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin, Jpn J Clin Hematol, 35: 635-641, 1994.
11. Smithers DW: Summary of papers delivered at the Conference on Staging in Hodgkin's disease (Ann Arbor), Cancer Res, 31: 1896-1870, 1971.
12. Liang R, Todd D, Chan TK, et al: Treatment outcome and prognostic factors for primary nasal lymphoma, J Clin Oncol, 13: 666-670, 1995.
13. Makita M, Maeda Y, Takenaka K, et al: Successful treatment of progressive NK cell lymphoma with allogeneic peripheral stem cell transplantation followed by early cyclosporine tapering and donor leukocyte infusions, Int J Hematol, 76: 94-97, 2002.
14. Kim GE, Cho JH, Yang WI, et al: Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment, J Clin Oncol, 18: 54-63, 2000.
15. Sobrevilla-Calvo P, Meneses A, Alfaro P: Radiotherapy compared to chemotherapy as initial treatment of angiocentric centrofacial lymphoma (polymorphic reticulosis), Acta Oncol, 32: 69-72, 1993.
16. Ribrag V, Ell Hajj M, Janot F, et al: Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx, Leukemia, 15: 1123-1126, 2001.
17. Yamaguchi M, Ogawa S, Nomoto Y, et al: Treatment outcome of nasal NK-cell lymphoma: A report of 12 consecutively-diagnosed cases and a review of the literature, J Clin Exp Hematopathol, 41: 93-99, 2001.
18. Kwong YL, Chan ACL, Liang R, et al: CD56+NK lymphomas: Clinicopathological features and prognosis, Br J Haematol, 97: 821-829, 1997.
19. Yu KH, Yu SC, Teo PM, Chan AT, Yeo W, Chow J: Nasal lymphoma: Results of local radiotherapy with or without chemotherapy, Head Neck, 19: 251-259, 1997.
20. Aviles A, Diaz NR, Neri N, Cleto S, Talavera A: Angiocentric nasal T/natural killer cell lymphoma: A single centre study of prognostic factors in 108 patients, Clin Lab Haematol, 22: 215-220, 2000.
21. Shikama N, Izuno I, Oguchi M, et al: Clininal stage IE primary lymphoma of the nasal cavity: Radiation therapy and chemotherapy, Radiology, 204: 467-470, 1997.
22. Takasu S, Wakabayashi T, Kajita Y, et al: Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma, No Shinkei Geka, 28: 789-794, 2000.